Ruxolitinib treatment ameliorates clinical, immunologic, and transcriptomic aberrations in patients with STAT3 gain-of-function disease.
Bayram Catak F, Catak MC, Babayeva R, Toubia J, Warnock NI, Celmeli F, Hafizoglu D, Yakici N, Kayaoglu B, Surucu N, Yalcin Gungoren E, Can S, Yorgun Altunbas M, Karakus IS, Kiykim A, Orhan F, Bilgic Eltan S, Karakoc-Aydiner E, Ozen A, Erman B, Gursel M, Kok CH, Cildir G, Baris S.
Bayram Catak F, et al. Among authors: ozen a.
J Allergy Clin Immunol. 2024 Dec 2:S0091-6749(24)01284-3. doi: 10.1016/j.jaci.2024.11.032. Online ahead of print.
J Allergy Clin Immunol. 2024.
PMID: 39631446